Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 9/20 | 0.53 |
| ▸ | CACNA1G | O43497 | 8/20 | 0.53 |
| ▸ | CACNA1H | O95180 | 8/20 | 0.53 |
| ▸ | DRD4 | P21917 | 4/20 | 0.48 |
| ▸ | GFER | P55789 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3300192 | 0.90 | DRD4 (0.49) | KCNH2CACNA1GCACNA1HDRD4GFER | |
| SCHEMBL3300454 | 0.88 | CACNA1G (0.60) | KCNH2CACNA1GCACNA1HGFERHTR6 | |
| SCHEMBL3299917 | 0.87 | CACNA1G (0.53) | KCNH2CACNA1GCACNA1HDRD2HTR6 | |
| SCHEMBL3296701 | 0.87 | DRD4 (0.54) | DRD4GFERDRD2DRD3ALDH1A1 | |
| SCHEMBL3301941 | 0.84 | ALDH1A1 (0.58) | KCNH2CACNA1GCACNA1HDRD4DRD2 | |
| SCHEMBL3298095 | 0.83 | KCNH2 (0.55) | KCNH2CACNA1GCACNA1HGFERHTR6 | |
| SCHEMBL3298256 | 0.83 | ALDH1A1 (0.55) | KCNH2CACNA1GCACNA1HDRD4DRD2 | |
| SCHEMBL26131428 | 0.82 | KCNH2 (0.62) | KCNH2CACNA1GCACNA1HGFERHTR6 | |
| SCHEMBL3301932 | 0.82 | GFER (0.55) | KCNH2CACNA1GCACNA1HDRD4GFER | |
| SCHEMBL3304244 | 0.81 | MEN1 (0.57) | KCNH2CACNA1GCACNA1HHTR6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299072-B2 | Pyrazolylmethylamine compounds as calcium channel modulators and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-10-30 | — | — | US | disclosed |
| US-20100094006-A1 | NOVEL PYRAZOLYLMETHYLAMINE COMPOUNDS AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100094006-A1 | NOVEL PYRAZOLYLMETHYLAMINE COMPOUNDS AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF | CACNA1I, CACNA1C, ORAI1 | KCNH2 69/4885CACNA1G 7/4885CACNA1H 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.